Adial Pharmaceuticals Set for H.C. Wainwright Conference 2024
![Adial Pharmaceuticals Set for H.C. Wainwright Conference 2024](https://investorshangout.com/images/blog/ihnews-Adial%20Pharmaceuticals%20Set%20for%20H.C.%20Wainwright%20Conference%202024.jpg)
Adial Pharmaceuticals to Showcase Innovations at Conference
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a prominent player in the biopharmaceutical sector focused on addiction therapies, is gearing up to present at the H.C. Wainwright 26th Annual Global Investment Conference. This significant event will take place from September 9-11, 2024, in a prestigious venue located in New York City.
CEO's Presentation Details
Cary Claiborne, the CEO of Adial Pharmaceuticals, will be at the forefront of this presentation, which aims to highlight the company's innovative treatment options aimed at combating addiction and related disorders. Registered attendees will have the opportunity to access the presentation on-demand through the conference platform starting September 9, 2024, at 7:00 AM Eastern Time.
Adial's Commitment to Addiction Treatment
Adial Pharmaceuticals is renowned for its dedication to developing treatments for addiction, using scientific rigor and innovation. The Company’s leading investigational product, AD04, is paving the way in this sector. This drug is a serotonin-3 receptor antagonist designed to treat Alcohol Use Disorder (AUD) specifically in heavy drinkers. The promising outcomes from the ONWARD™ pivotal Phase 3 clinical trial have shown its efficacy in reducing the frequency of heavy drinking, providing hope for many patients.
Examining Results and Future Potential
The ONWARD study not only highlighted AD04's ability to minimize heavy drinking but also demonstrated a favorable safety profile. Moreover, AD04 is believed to hold potential for treating other types of addictions, including Opioid Use Disorder, gambling addiction, and obesity, underscoring Adial’s ambitions to expand its impact in the addiction treatment landscape.
Engagement with Investors
Throughout the conference, Adial’s management team will actively engage in one-on-one meetings with investors, seeking to forge valuable connections within the investment community. Interested parties wishing to schedule a meeting are encouraged to reach out directly to Adial's communications team.
Contact for Investor Relations
For inquiries regarding meetings or further information, potential investors can contact Adial’s investor relations via email. Furthermore, more extensive details about Adial Pharmaceuticals and their innovative treatment solutions can be found at their official website.
Frequently Asked Questions
What is Adial Pharmaceuticals focused on?
Adial Pharmaceuticals is dedicated to developing therapies for addiction treatment and prevention.
When will Adial present at the conference?
Adial's presentation will be available on-demand starting September 9, 2024, at 7:00 AM Eastern Time.
What is the significance of AD04?
AD04 is an investigational treatment aimed at addressing Alcohol Use Disorder and shows potential for treating other addictions.
How can investors connect with Adial during the conference?
Investors can schedule one-on-one meetings with management by reaching out to the company’s investor relations team.
Where can I find more information about the company?
Additional information about Adial Pharmaceuticals can be found on their official website.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Court TV Announces Exciting Fall Primetime Lineup for 2024
- Mediaspace.global Launches Changemakers' Summit for 2024
- MALK Organics Launches Almond Pumpkin Spice for Fall 2024
- Accorto Regulatory Solutions Partners with GINN for Tobacco Safety
- Carterra Ultra™: Transforming Drug Discovery with Precision
- Opus IVS DrivePro 2 Achieves Motor Top 20 Award for 2024
- Autograph Revolutionizes Sports Fandom with New Platform
- Attain Capital Welcomes Former NASA CIO Renee P. Wynn
- ICEYE and Aon Join Forces to Boost Flood and Wildfire Response
- Laurence Moroney to Speak at Info-Tech LIVE 2024 Conference
- Philadelphia Fed Initiates Search for New President Following Harker
- PhotonPharma Showcases Innovative Cancer Therapies Conference
- Blaze Mota Unveils THC-Infused Mota'lada for Everyone
- Adam Neumann and Ryan Serhant to Speak at South Florida Forum
- Unilever Secures Approval to Sell Russian Assets Amid Criticism
- Growth Prospects for Global Furniture Fittings Market Ahead
- Industrial Cooling Systems Market Set for Remarkable Growth
- Tarkett Receives Platinum Medal from EcoVadis for Sustainability
- Integra LifeSciences Prepares for 2024 Wells Fargo Event
- Gong Named Leader in Revenue Orchestration Platforms by Forrester
- Microban International Partners with CiCLO for Sustainable Textiles
- Autoinjectors Market Forecast to Reach USD 3.02 Billion by 2030
- NPCI Showcases Digital Payment Innovations at GFF 2024
- Middie Rising: A New Narrative for Schools in Transition
- Insider Buying: Two Stocks to Watch for Potential Gains
Recent Articles
- Moon Gaming Inc. Unveils Moon Poker: Exciting Tournaments Ahead
- Attain Capital Welcomes Former NASA CIO Renee P. Wynn
- BIDFTA.COM Expands Auction Services with Bargain Hunt Deal
- Adam Neumann and Ryan Serhant to Speak at South Florida Forum
- Unilever Secures Approval to Sell Russian Assets Amid Criticism
- Kontakt.io Revolutionizes Asset Tracking with Sticker Tag
- Warren Buffett's Hidden Investment in Chubb Insurance Revealed
- Yoga Clothing Market Projected to Exceed USD 58.38 Billion
- Experience Romance at Fairmont Orchid Inspired by 'The Bachelorette'
- Binswanger Welcomes Brooke Oldt as Senior VP of Corporate Services
- Randstad US Study: Political Conversations and Workplace Safety
- Steve Varsano Receives Aviator Award for Lifetime Achievement
- Citadel's Wellington Fund Gains 1% Amid Volatile August
- Evoke Pharma to Showcase Innovations in Investment Conference
- KommuneKredit Reports Impressive H1 2024 Financial Results
- Cetaphil Unveils Gentle Exfoliating Line Featuring Katie Fang
- Nasdaq 100 Faces Pressure from Nvidia's Market Impact
- Market Turbulence: U.S. Economic Outlook Sparks Concerns
- Montana Technologies Partners with Clairity for Climate Solutions
- Biofidelity Strengthens Leadership Team with Key Appointments
- Exciting New Joint Venture: The Nemeth Bros Podcast Launch
- Automotive Automatic Transmission Market: Growth and Trends
- Daktronics, Inc. Reports Strong Q1 2025 Financial Results
- Biogen Releases Promising Results for Nusinersen in SMA Treatment
- Conagra Brands Announces First Quarter Earnings Release Date